'''Radiopharmacology''' is the study and preparation of '''radiopharmaceuticals''', which are [[radioactivity|radioactive]] [[pharmaceutical]]s. Radiopharmaceuticals are used in the field of [[nuclear medicine]] as tracers in the diagnosis and treatment of many [[disease]]s. Many radiopharmaceuticals use [[technetium-99m]] (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide. In the book '''Technetium''' a total of 31 different radiopharmaceuticals based on Tc-99m are listed for imaging and functional studies of the [[brain]], [[myocardium]], [[thyroid]], [[lungs]], [[liver]], [[gallbladder]], [[kidneys]], [[skeleton]], [[blood]] and [[tumor]]s.<ref>Schwochau, Klaus. ''Technetium''. Wiley-VCH (2000). ISBN 3-527-29496-1</ref>

The term '''''radioisotope''''' has historically been used to refer to all radiopharmaceuticals, and this usage remains common. Technically, however, many radiopharmaceuticals incorporate a [[radioactive tracer]] atom into a larger pharmaceutically-active molecule, which is localized in the body, after which the radionuclide tracer atom allows it to be easily detected with a [[gamma camera]] or similar gamma imaging device. An example is [[fludeoxyglucose]] in which [[fluorine-18]] is incorporated into deoxyglucose. Some radioisotopes (for example [[gallium-67]], [[gallium-68]], and [[radioiodine]]) are used directly as soluble ionic salts, without further modification. This use relies on the chemical and biological properties of the radioisotope itself, to localize it within the body.[[File:Lead container for nuclear medications.jpg|thumb|200px|right|Lead container for iodine-123 capsule]]

==History==
See [[nuclear medicine]].

==Production==

Production of a radiopharmaceutical involves two processes:

* The production of the [[radionuclide]] on which the pharmaceutical is based.

* The preparation and packaging of the complete radiopharmaceutical.

Radionuclides used in radiopharmaceuticals are mostly radioactive [[isotopes]] of elements with atomic numbers less than that of [[bismuth]], that is, they are radioactive isotopes of elements that also have one or more stable isotopes. These may be roughly divided into two classes:

* Those with excess neutrons in the nucleus to those required for stability are known as '''proton-deficient''', and tend to be most easily produced in a [[nuclear reactor]], the majority of radiopharmaceuticals are based on proton deficient isotopes, with [[technetium-99m]] being the most commonly used medical isotope, and therefore nuclear reactors are the prime source of medical [[radioisotopes]].<ref>http://www.sciencedaily.com/releases/2010/07/100708111326.htm</ref>

* Those with fewer neutrons in the nucleus to those required for stability are known as '''neutron-deficient''', and tend to be most easily produced using a proton accelerator such as a medical [[cyclotron]].

== Practical use ==
Because radiopharmeuticals require special licenses and handling techniques, they are often kept in local centers for medical radioisotope storage, often known as [[radiopharmacy|radiopharmacies]]. A [[radiopharmacist]] may dispense them from there, to local centers where they are handled at the [[practical medicine]] facility.

==Specific radiopharmaceuticals==

A list of '''nuclear medicine radiopharmaceuticals''' follows. Some radioisotopes* are used in [[ion]]ic or [[inert]] form without attachment to a pharmaceutical, these are also included. There is a section for each [[radioisotope]] with a table of radiopharmaceuticals using that radioisotope. The sections are ordered alphabetically by the English name of the radioisotope. Sections for the same [[Chemical element|element]] are then ordered by [[atomic mass number]].

===Calcium-47===
<sup>47</sup>[[Calcium|Ca]] is a [[Beta particle|beta]] and [[Gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Ca-47-Ca<sup>2+</sup>
|Bone metabolism
|IV
|''In-vitro'' 
|Non-imaging
|}

===Carbon-11===
<sup>11</sup>[[Carbon|C]] is a [[positron]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|C11-L-methyl-methionine
|Brain tumour imaging<br>
Parathyroid imaging
|IV
|''In-vivo''
|Imaging
|}

===Carbon-14===
[[Carbon-14|<sup>14</sup>C]] is a [[Beta particle|beta]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|C14-[[Glycocholic acid]]
|Breath test for small intestine bacterial overgrowth
|Oral
|''In-vitro''
|Non-imaging
|-
|C14-PABA (para-amino benzoic acid)
|Pancreatic studies
|Oral
|''In-vitro''
|Non-imaging
|-
|C14-Urea
|Breath test to detect ''Helicobacter pylori''
|Oral
|''In-vitro''
|Non-imaging
|-
|C14-d-xylose
|Breath test for small intestine bacterial overgrowth
|Oral
|''In-vitro''
|Non-imaging
|}

===Chromium-51===
[[Chromium|<sup>51</sup>Cr]] is a [[Gamma ray|gamma]] emitter.
{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Cr51-[[Red blood cell]]s
|Red cell volume; sites of sequestration; gastrointestinal blood loss
|IV
|''In-vitro'' 
|Non-imaging
|-
|Cr51-Cr<sup>3+</sup>
|Gastrointestinal protein loss
|IV
|''In-vitro'' 
|Non-imaging
|-
|Cr51-[[EDTA]] (ethylenediaminetetraacetic acid)
|[[Glomerular filtration rate]] measurement
|IV
|''In-vitro'' 
|Non-imaging
|}

===Cobalt-57===
[[Cobalt|<sup>57</sup>Co]] is a [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Co57-[[Cyanocobalamin]] (vitamin B<sub>12</sub>)
|Gastrointestinal absorption
|Oral
|''In-vitro'' 
|Non-imaging
|}

===Cobalt-58===
[[Cobalt|<sup>58</sup>Co]] is a [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Co58-[[Cyanocobalamin]] (vitamin B<sub>12</sub>)
|Gastrointestinal absorption
|Oral
|''In-vitro'' 
|Non-imaging
|}

===Erbium-169===
[[Erbium|<sup>169</sup>Er]] is a [[beta particle|beta]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Treatment of
!Route of administration
|-
|Er169-Colloid
|Arthritic conditions
|Intra-articular
|}

===Fluorine-18===
[[Fluorine-18|<sup>18</sup>F]] is a [[positron]] emitter with a half life of 109 minutes. It is produced in medical cyclotrons, usually from oxygen-18, and then chemically attached to a pharmaceutical. See [[PET scan]].

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|F18-FDG ([[Fluorodeoxyglucose]])
|Tumor imaging<br>
Myocardial imaging
|IV
|''In-vivo'' 
|Imaging
|-
|F18-Sodium Fluoride
|Bone imaging
|IV
|''In-vivo'' 
|Imaging
|-
|F18-Fluorocholine
|Prostate tumor imaging
|IV
|''In-vivo''
|Imaging
|}

===Gallium-67===
[[Gallium|<sup>67</sup>Ga]] is a [[gamma ray|gamma]] emitter. See [[gallium scan]].

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Ga67-Ga<sup>3+</sup>
|Tumor imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Ga67-Ga<sup>3+</sup>
|Infection/inflammation imaging
|IV
|''In-vivo'' 
|Imaging
|}

===Gallium-68===
[[Gallium|<sup>68</sup>Ga]] is a [[positron]] emitter, with a 68 minute [[half life]], produced by [[elution]] from germanium-68 in a [[gallium-68 generator]]. See also [[positron emission tomography]].

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Ga68-Dotatoc or Dotatate
|[[Neuroendocrine tumor]] imaging
|IV
|''In-vivo'' 
|Imaging
|}

===Hydrogen-3===
<sup>3</sup>H or [[tritium]] is a [[beta particle|beta]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|H3-water
|Total body water
|Oral or IV
|''In-vitro'' 
|Non-imaging
|}

===Indium-111===
[[Indium|<sup>111</sup>In]] is a [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|In111-DTPA ([[DTPA|diethylenetriaminepenta-acetic acid]])
|Ventriculo-peritoneal shunt (LaVeen Shunt)
|intraperitoneal injection
|''In-vivo'' 
|Imaging
|-
|In111-DTPA ([[DTPA|diethylenetriaminepenta-acetic acid]])
|Cisternography
|Intra-cisternal
|''In-vivo'' 
|Imaging
|-
|In111-[[Leukocyte]]s
|Infection/inflammation imaging
|IV
|''In-vivo'' 
|Imaging
|-
|In111-[[Platelet]]s
|Thrombus imaging
|IV
|''In-vivo'' 
|Imaging
|-
|In111-Pentetreotide
|[[Somatostatin]] receptor imaging
|IV
|''In-vivo'' 
|Imaging
|-
|In111-Octreotide
|[[Somatostatin]] receptor imaging ([[Octreoscan]])
|IV
|''In-vivo'' 
|Imaging
|}

===Iodine-123===
[[Iodine|<sup>123</sup>I]] is a [[gamma ray|gamma]] emitter. It is used only diagnostically, as its radiation is penetrating and short-lived.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|I123-Iodide
|[[Thyroid]] uptake
|Oral or IV
|''In-vivo'' 
|Non-imaging
|-
|I123-Iodide
|Thyroid imaging<br>
Thyroid [[metastasis|metastases]] imaging
|Oral or IV
|''In-vivo'' 
|Imaging
|-
|I123-o-Iodohippurate
|Renal imaging
|IV
|''In-vivo'' 
|Imaging
|-
|I123-MIBG (m-iodobenzylguanidine)
|Neuroectodermal tumour imaging
|IV
|''In-vivo'' 
|Imaging
|-
|I123-FP-CIT
|SPECT imaging of Parkinson's Disease
|IV
|''In-vivo''
|Imaging
|}

===Iodine-125===
[[Iodine|<sup>125</sup>I]] is a [[gamma ray|gamma]] emitter with a long half-life of 59.4 days (the longest of all radioiodines used in medicine). Iodine-123 is preferred for imaging, so I-125 is used diagnostically only when the test requires a longer period to prepare the radiopharmaceutical and trace it, such as a [[fibrinogen scan]] to diagnose clotting. I-125's gamma radiation is of medium penetration, making it more useful as a therapeutic isotope for [[brachytherapy]] implant of radioisotope capsules for local treatment of cancers.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|I125-fibrinogen
|Clot imaging
|IV
|''In-vivo'' 
|Imaging
|-
|}

===Iodine-131===
[[Iodine-131|<sup>131</sup>I]] is a [[beta particle|beta]] and [[gamma ray|gamma]] emitter. It is used both to destroy thyroid and thyroid cancer tissues (via beta radiation, which is short-range), and also other neuroendocrine tissues when used in MIBG. It can also be seen by a gamma camera, and can serve as a diagnostic imaging tracer, when treatment is also being attempted at the same time. However iodine-123 is usually preferred when '''only''' imaging is desired.

====Diagnostic====
{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|I131-Iodide
|[[Thyroid]] uptake
|Oral
|''In-vivo'' 
|Non-imaging
|-
|I131-Iodide
|Thyroid [[metastasis|metastases]] imaging
|Oral or IV
|''In-vivo'' 
|Imaging
|-
|I131-MIBG (m-iodobenzylguanidine)
|Neuroectodermal tumor imaging
|IV
|''In-vivo'' 
|Imaging
|}

====Therapeutic====
{| class="wikitable" style="font-size:95%"
|-
!Name
!Treatment of
!Route of administration
|-
|I131-Iodide
|[[Thyrotoxicosis]]
|IV or Oral
|-
|I131-Iodide
|Non-toxic [[goiter]]
|IV or Oral
|-
|I131-Iodide
|[[Thyroid cancer|Thyroid carcinoma]]
|IV or Oral
|-
|I131-MIBG (m-iodobenzylguanidine)
|Malignant disease
|IV
|}

===Iron-59===
[[Iron|<sup>59</sup>Fe]] is a [[beta particle|beta]] and [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Fe59-Fe<sup>2+</sup> or Fe<sup>3+</sup>
|Iron metabolism
|IV
|''In-vitro'' 
|Non-imaging
|}

===Krypton-81m===
[[Krypton|<sup>81</sup>Kr<sup>m</sup>]] is a [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Kr81m-Gas
|Lung ventilation imaging
|Inhalation
|''In-vivo'' 
|Imaging
|-
|Kr-81m-Aqueous solution
|Lung perfusion imaging
|IV
|''In-vivo'' 
|Imaging
|}

===Nitrogen-13===
[[Nitrogen-13|<sup>13</sup>N]] is a [[positron]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|N13-[[Ammonia]]
|Myocardial blood flow imaging
|IV
|''In-vivo'' 
|Imaging
|}

===Oxygen-15===
[[Oxygen|<sup>15</sup>O]] is a [[positron]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|O15-Water
|Cerebral blood flow imaging<br>
Myocardial blood flow imaging
|IV bolus
|''In-vivo'' 
|Imaging
|}

===Phosphorus-32===
[[Phosphorus|<sup>32</sup>P]] is a [[beta particle|beta]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Treatment of
!Route of administration
|-
|P32-Phosphate
|[[Polycythemia]] and related disorders
|IV or Oral
|}

===Rubidium-82===
[[Rubidium|<sup>82</sup>Rb]] is a [[positron]] and [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Treatment of
!Route of administration
|-
|[[Rb-82 Chloride]] 
|Myocardial Imaging
|IV
|}

===Samarium-153===
[[Samarium|<sup>153</sup>Sm]] is a [[beta particle|beta]] and [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Treatment of
!Route of administration
|-
|[[Samarium-153-ethylene diamine tetramethylene phosphonate|Sm153-EDTMP]] (Ethylenediaminotetramethylenephosphoric acid)
|Bone metastases
|IV
|}

===Selenium-75===
[[Selenium|<sup>75</sup>Se]] is a [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Se75-Selenorcholesterol
|[[Adrenal gland]] imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Se75-[[SeHCAT]] (23-Seleno-25-homo-tauro-cholate)
|[[Bile salt]] absorption
|Oral
|''In-vivo'' 
|Imaging
|}

===Sodium-22===
[[Sodium|<sup>22</sup>Na]] is a [[positron]] and [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Na22-Na<sup>+</sup>
|Electrolyte studies
|Oral or IV
|''In-vitro'' 
|Non-imaging
|}

===Sodium-24===
[[Sodium|<sup>24</sup>Na]] is a [[beta particle|beta]] and [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Na24-Na<sup>+</sup>
|Electrolyte studies
|Oral or IV
|''In-vitro'' 
|Non-imaging
|}

===Strontium-89===
[[Strontium|<sup>89</sup>Sr]] is a [[beta particle|beta]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Treatment of
!Route of administration
|-
|Sr89-Chloride
|Bone metastases
|IV
|}

===Technetium-99m===
[[Technetium|<sup>99</sup>Tc]] is a [[gamma ray|gamma]] emitter. It is obtained on-site at the imaging center as the soluble pertechnetate which is eluted from a [[technetium-99m generator]], and then either used directly as this soluble salt, or else used to synthesize a number of [[technetium-99m]]-based radiopharmaceuticals. 

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Tc99m-[[pertechnetate]]
|[[Thyroid]] uptake and thyroid imaging<br>
Stomach and salivary gland imaging<br>
[[Meckel's diverticulum]] imaging<br>
Brain imaging<br>
Micturating cystogram<br>
First pass blood flow imaging<br>
First pass peripheral vascular imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-pertechnetate
|Lacrimal imaging
|Eye drops
|''In-vivo'' 
|Imaging
|-
|Tc99m-[[Human serum albumin|Human albumin]]
|Cardiac blood pool imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Human albumin
|Peripheral vascular imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Human albumin macroaggregates or microspheres
|Lung perfusion imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Human albumin macroaggregates or microspheres
|Lung perfusion imaging with venography
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Phosphonates and phosphates
|Bone imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Phosphonates and phosphates
|Myocardial imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-[[DTPA]] (diethylenetriaminepenta-acetic acid)
|Renal imaging<br>First pass blood flow studies<br>Brain imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-[[DTPA]] (diethylenetriaminepenta-acetic acid)
|Lung ventilation imaging
|Aerosol inhalation
|''In-vivo'' 
|Imaging
|-
|Tc99m-DMSA(V) ([[dimercaptosuccinic acid]])
|Tumor imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-DMSA(III) ([[dimercaptosuccinic acid]])
|Renal imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Colloid
|Bone marrow imaging<br>
GI Bleeding
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Colloid
|Lymph node imaging
|Interstitial
|''In-vivo'' 
|Imaging
|-
|Tc99m-Colloid
|Esophageal transit and reflux imaging<br>
Gastric emptying imaging
|Oral
|''In-vivo'' 
|Imaging
|-
|Tc99m-Colloid
|Lacrimal imaging
|Eye drops
|''In-vivo'' 
|Imaging
|-
|Tc99m-HIDA (Hepatic iminodiacetic acid)
|Functional biliary system imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Denatured red bood cells
|Red cell volume
|IV
|''In-vitro'' 
|Non-imaging
|-
|Tc99m-Red blood cells
|GI bleeding<br>
[[MUGA scan|Cardiac blood pool imaging]]<br>
Peripheral vascular imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-MAG3 (mercaptoacetyltriglycine)
|Renal imaging<br>
First pass blood flow imaging<br>
|IV
|''In-vivo'' 
|Imaging
|-
|[[Technetium (99mTc) exametazime|Tc99m-Exametazime]]
|Cerebral blood flow imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Exametazime labelled leucocytes
|Infection/inflammation imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-[[Sestamibi]] (MIBI - methoxy isobutyl isonitrile)
|[[Sestamibi scan|Parathyroid imaging]]<br>
Non-specific tumor imaging<br>
Thyroid tumor imaging<br>
Breast imaging<br>
Myocardial imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Sulesomab (IMMU-MN3 murine Fab'-SH antigranulocyte monoclonal antibody fragments)
|Infection/inflammation imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Technegas
|Lung ventilation imaging
|Inhalation
|''In-vivo'' 
|Imaging
|-
|Tc99m-Human immunoglobulin
|Infection/inflammation imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-Tetrofosmin
|Parathyroid imaging<br>
Myocardial imaging
|IV
|''In-vivo'' 
|Imaging
|-
|Tc99m-ECD (ethyl cysteinate dimer)
|Brain imaging-----
|IV
|''In-vivo'' 
|Imaging
|}...

===Thallium-201===
[[Thallium|<sup>201</sup>Tl]] is a [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Tl201-Tl<sup>+</sup>
|Non-specific tumor imaging<br>
Thyroid tumor imaging<br>
Myocardial imaging<br>
Parathyroid imaging
|IV
|''In-vivo'' 
|Imaging
|}

===Xenon-133===
[[Xenon|<sup>133</sup>Xe]] is a [[gamma ray|gamma]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Investigation
!Route of administration
!''In-vitro'' / ''in-vivo''
!Imaging / non-imaging
|-
|Xe133-gas
|Lung ventilation studies
|Inhalation
|''In-vivo'' 
|Imaging
|-
|Xe133 in isotonic sodium chloride solution
|Cerebral blood flow
|IV
|''In-vivo'' 
|Imaging
|}

===Yttrium-90===
[[Yttrium|<sup>90</sup>Y]] is a [[beta particle|beta]] emitter.

{| class="wikitable" style="font-size:95%"
|-
!Name
!Treatment of
!Route of administration
|-
|Y90-Silicate
|Arthritic conditions
|Intra-articular
|-
|Y90-Silicate
|Malignant disease
|Intracavitary
|}

==See also==
*[[Radioactive tracer]]
*[[Nuclear medicine]]

==References==
{{reflist}}

== Reading ==
*Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of radioactive substances advisory committee. March 2006. Produced by the Health Protection Agency.
* [http://www.merck.com/mrkshared/mmg/sec13/ch111/ch111a.jsp Malabsorption]. In: The Merck Manual of Geriatrics, chapter 111.
* [http://www.emea.europa.eu/humandocs/PDFs/EPAR/leukoscan/H-111-PI-en.pdf Leukoscan summary of product characteristics] (Tc99m-Sulesomab).
* Schwochau, Klaus. ''Technetium''. Wiley-VCH (2000). ISBN 3-527-29496-1

== External links ==
* [http://isotopes.gov/ National Isotope Development Center] U.S. Government resources for isotopes - production, distribution, and information
* [http://science.energy.gov/np/research/idpra/ Isotope Development & Production for Research and Applications (IDPRA)] U.S. Department of Energy program sponsoring isotope production and production research and development

{{Radiopharmaceuticals}}
{{Therapeutic radiopharmaceuticals}}
[[Category:Radiopharmaceuticals]]
[[Category:Radiobiology]]
[[Category:Radiation therapy]]